Drug Scandal Shocks France - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Drug Scandal Shocks France
Scandals regarding diabetes treatment Mediator frequently dominate French press headlines. Mediator was only withdrawn from the French market in November 2009, despite reports dating back as far as the 1990s linking similar products to valvular heart disease and pulmonary arterial hypertension. The end result is a great dissatisfaction among the French public with the French medicines regulator and the pharmaceutical industry, prompting a thorough reform of the country's pharmacovigilance system.


Pharmaceutical Technology Europe
Volume 23, Issue 3

References

1. EMA, "Questions and answers on the withdrawal of medicines containing benfluorex" (2010). http://www.ema.europa.eu

2. Inpharm, "Servier's Mediator provokes French drug safety controversy" (2010). http://www.inpharm.com

3. D.J. Heal, J. Gosden and S.L. Smith, Br. J Clin. Pharmacol., 68(6), 861–874 (2009).

4. FDA, "Questions and Answers about Withdrawal of Fenfluramine (Pondimin) and Dexfenfluramine (Redux)" (1997). http://www.fda.gov

5. Libération, "Un mal rare pour quelques kilos de trop" (2000). http://www.liberation.fr

6. J.R. Ribera et al., Rev. Esp. Cardiol., 56(2), 215–6 (2003).

7. Le Figaro, "Mediator: l'Assurance maladie mettait en garde dès 1998" (2011). http://www.lefigaro.fr

8. Le Post, "Mediator: Jacques Servier a-t-il financé Nicolas Sarkozy et l'UMP?" (2010). http://www.lepost.fr

9. Le Monde, "Mediator: Xavier Bertrand annonce une réforme de la pharmaco-vigilance" (2011). http://www.lemonde.fr


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
11%
Protecting the supply chain
37%
Expedited reviews of drug submissions
11%
More stakeholder involvement
11%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology Europe,
Click here